Update on Surveillance in Von Hippel–Lindau Disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs. This neoplasia leads to significant morbidity and potential mortality in affected individuals. Tumor surveillance enables early intervention and leads to improved clinical outcomes. Since the 2017 publication of VHL tumor surveillance recommendations from the inaugural American Association for Cancer Research Childhood Cancer Predisposition Workshop, several other groups have proposed alternative consensus surveillance recommendations. Although these screening paradigms share some common elements, they also deviate from each other in some substantial ways. Clinical data continue to accrue in VHL, allowing the condition to be better characterized. Furthermore, surgical techniques have improved over time, and the option of targeted medical therapy has emerged for individuals with VHL. It is critical that surveillance strategies continue to be refined. In this perspective, we provide an up-to-date clinical overview of VHL, describe recently proposed tumor screening regimens, and finally present our updated consensus tumor surveillance recommendations during childhood and adolescence from the 2023 American Association for Cancer Research Childhood Cancer Predisposition Workshop.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Flynn, J. T., Kaelber, D. C., Baker-Smith, C. M., Blowey, D., Carroll, A. E., Daniels, S. R., de Ferranti, S. D., Dionne, J. M., Falkner, B., Flinn, S. K., et al. (2017) · Pediatrics · doi:10.1542/peds.2017-1904 · Cited by 3,651
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714
Research works printed but not linked: 48
- Maher, 2011, von Hippel-Lindau disease: a clinical and scientific review, Eur J Hum Genet, 19, 617, 10.1038/ejhg.2010.175 · DOI · Paper page
- Kaelin, 2017, The VHL tumor suppressor gene: insights into oxygen sensing and cancer, Trans Am Clin Climatol Assoc, 128, 298
- Maher, 1991, Von Hippel-Lindau disease: a genetic study, J Med Genet, 28, 443, 10.1136/jmg.28.7.443 · DOI · Paper page
- Binderup, 2022, von Hippel-Lindau disease: updated guideline for diagnosis and surveillance, Eur J Med Genet, 65, 104538, 10.1016/j.ejmg.2022.104538 · DOI · Paper page
- Launbjerg, 2017, von Hippel-Lindau development in children and adolescents, Am J Med Genet A, 173, 2381, 10.1002/ajmg.a.38324 · doi:10.1002/ajmg.a.38324
- Poulsen, 2010, Surveillance in von Hippel-Lindau disease (vHL), Clin Genet, 77, 49, 10.1111/j.1399-0004.2009.01281.x · doi:10.1111/j.1399-0004.2009.01281.x
- Maher, 1990, Clinical features and natural history of von Hippel-Lindau disease, Q J Med, 77, 1151, 10.1093/qjmed/77.2.1151 · DOI · Paper page
- Kreusel, 2005, Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications, Fam Cancer, 4, 43, 10.1007/s10689-004-1327-0 · DOI
- Kreusel, 2006, Retinal angiomatosis in von Hippel-Lindau disease: a longitudinal ophthalmologic study, Ophthalmology, 113, 1418, 10.1016/j.ophtha.2006.02.059 · doi:10.1016/j.ophtha.2006.02.059
- Binderup, 2013, Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition, Dan Med J, 60, B4763
- Binderup, 2018, von Hippel-Lindau disease: diagnosis and factors influencing disease outcome, Dan Med J, 65, B5461
- Nielsen, 2016, Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome, J Clin Oncol, 34, 2172, 10.1200/JCO.2015.65.6140 · DOI · Paper page
- Daniels, 2023, Consensus guidelines for ocular surveillance of von Hippel-Lindau disease, Ophthalmology, 131, 622, 10.1016/j.ophtha.2023.12.014 · DOI · Paper page
- Huntoon, 2014, Findings from the natural history of central nervous system hemangioblastomas in von Hippel-Lindau disease, Neurosurgery, 61, N159, 10.1227/NEU.0000000000000384 · doi:10.1227/neu.0000000000000384
- Lonser, 2014, Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease, J Neurosurg, 120, 1055, 10.3171/2014.1.JNS131431 · DOI · Paper page
- Takayanagi, 2022, Hemangioblastoma and Von Hippel-Lindau disease, No Shinkei Geka, 50, 101
- Knoblauch, 2024, Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease, J Neurooncol, 168, 537, 10.1007/s11060-024-04676-5 · DOI · Paper page
- Li, 2020, Clinical and biochemical features of pheochromocytoma characteristic of Von Hippel-Lindau syndrome, World J Surg, 44, 570, 10.1007/s00268-019-05299-y · DOI
- Ashouri, 2015, Implications of Von Hippel-Lindau syndrome and renal cell carcinoma, J Kidney Cancer VHL, 2, 163, 10.15586/jkcvhl.2015.41 · DOI
- Kwon, 2014, Renal tumor size is an independent prognostic factor for overall survival in Von Hippel-Lindau disease, J Cancer Res Clin Oncol, 140, 1171, 10.1007/s00432-014-1654-y · doi:10.1007/s00432-014-1654-y
- Chahoud, 2021, Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease, World J Urol, 39, 2409, 10.1007/s00345-020-03441-3 · DOI
- O’Toole, 2018, Paediatric pancreatic neuroendocrine tumours in von Hippel-Lindau disease, Endocr Relat Cancer, 25, L43, 10.1530/ERC-18-0123 · doi:10.1530/erc-18-0123
- Zwolak, 2020, Pancreatic neuroendocrine tumours in patients with von Hippel-Lindau disease, Endokrynol Pol, 71, 256, 10.5603/EP.a2020.0027 · doi:10.5603/ep.a2020.0027
- Krauss, 2018, Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors, Endocr Relat Cancer, 25, 783, 10.1530/ERC-18-0100 · DOI
- Bausch, 2016, Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry, Head Neck, 38, E673
- Mehta, 2022, Endolymphatic sac tumor screening and diagnosis in von Hippel-Lindau disease: a consensus statement, J Neurol Surg B Skull Base, 83, e225, 10.1055/s-0041-1725033 · doi:10.1055/s-0041-1725033
- Binderup, 2017, Survival and causes of death in patients with von Hippel-Lindau disease, J Med Genet, 54, 11, 10.1136/jmedgenet-2016-104058 · DOI · Paper page
- Prasad, 2011, Pediatric endocrine screening for von Hippel-Lindau disease: benefits and the challenge of compliance, J Endocrinol Invest, 34, 296, 10.1007/BF03347089 · DOI
- Priesemann, 2006, Benefits of screening in von Hippel-Lindau disease—comparison of morbidity associated with initial tumours in affected parents and children, Horm Res, 66, 1
- Jamshidi, 2024, Belzutifan in individuals with von Hippel-Lindau retinal hemangioblastomas: institutional experience and review of the literature, Ocul Oncol Pathol, 10, 154, 10.1159/000539434 · DOI
- Kuzbari, 2023, Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations, Ann Oncol, 34, 215, 10.1016/j.annonc.2022.12.003 · DOI
- Wolters, 2022, Multidisciplinary integrated care pathway for von Hippel-Lindau disease, Cancer, 128, 2871, 10.1002/cncr.34265 · DOI · Paper page
- Bratslavsky, 2021, Genetic risk assessment for hereditary renal cell carcinoma: clinical consensus statement, Cancer, 127, 3957, 10.1002/cncr.33679 · doi:10.1002/cncr.33679
- Reaume, 2013, Canadian guideline on genetic screening for hereditary renal cell cancers, Can Urol Assoc J, 7, 319, 10.5489/cuaj.1496 · doi:10.5489/cuaj.1496
- Koeller, 2022, An optimized protocol for evaluating pathogenicity of VHL germline variants in patients suspected with von Hippel-Lindau syndrome: using somatic genome to inform the role of germline variants, MethodsX, 9, 101761, 10.1016/j.mex.2022.101761 · DOI
- Rana, 2021, Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: an integrated evaluation of germline and somatic genomic results, Eur J Med Genet, 64, 104359, 10.1016/j.ejmg.2021.104359 · DOI
- Zelley, 2024, Update on genetic counselor practice and recommendations for pediatric cancer predisposition evaluation and surveillance, Clin Cancer Res, 30, 3983, 10.1158/1078-0432.CCR-24-1165 · DOI
- Mougel, 2024, Update of the UMD-VHL database: classification of 164 challenging variants based on genotype-phenotype correlation among 605 entries, J Med Genet, 61, 378, 10.1136/jmg-2023-109550 · DOI
- Bento, 2018, Genetic basis of congenital erythrocytosis, Int J Lab Hematol, 40, 62, 10.1111/ijlh.12828 · DOI
- Rednam, 2017, Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood, Clin Cancer Res, 23, e68, 10.1158/1078-0432.CCR-17-0547 · DOI · Paper page
- Daniels, 2023, Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance, Cancer, 129, 2927, 10.1002/cncr.34896 · DOI · Paper page
- Johnson, 2012, Patterns of linear growth and skeletal maturation from birth to 18 years of age in overweight young adults, Int J Obes (Lond), 36, 535, 10.1038/ijo.2011.238 · doi:10.1038/ijo.2011.238
- Kruizinga, 2014, Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations, Endocr Relat Cancer, 21, 63, 10.1530/ERC-13-0308 · DOI
- Franscini, 2015, Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: relevance to the diagnosis of neuroblastoma, Pediatr Blood Cancer, 62, 587, 10.1002/pbc.25385 · DOI
- Peitzsch, 2019, Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: particular importance for early infancy, Clin Chim Acta, 494, 100, 10.1016/j.cca.2019.03.1620 · DOI
- Zuo, 2018, High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection, Clin Chim Acta, 478, 82, 10.1016/j.cca.2017.12.026 · DOI
- Sbardella, 2020, Random “spot” urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas, Eur J Endocrinol, 183, 129, 10.1530/EJE-19-0809 · DOI
- Boot, 2023, A laboratory medicine perspective on the investigation of phaeochromocytoma and paraganglioma, Diagnostics (Basel), 13, 2940, 10.3390/diagnostics13182940 · DOI
Metadata
- Authors
- Rednam, S. P., Becktell, K. D., Villani, A., Brodeur, G. M., States, L. J., Doria, A. S., Kamihara, J., Schneider, K. W., Voss, S. D., Widjaja, E., Zelley, K., Nakano, Y., Pajtler, K. W., Achatz, M. I., Malkin, D., Diller, L. R., Gallinger, B., Tamura, C., & Wasserman, J. D.
- Venue
- Clinical Cancer Research
- Published
- 2025-04-15
- Volume
- 31
- Issue
- 12
- Pages
- 2271-2277
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 17
- References
- 3
- Language
- en
- Funders
- St. Baldrick’s Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on Surveillance in Von Hippel–Lindau Disease. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-24-3525
- The paper
- Rednam, S. P., Becktell, K. D., Villani, A., Brodeur, G. M., States, L. J., Doria, A. S., Kamihara, J., Schneider, K. W., Voss, S. D., Widjaja, E., Zelley, K., Nakano, Y., Pajtler, K. W., Achatz, M. I., Malkin, D., Diller, L. R., Gallinger, B., Tamura, C., & Wasserman, J. D. (2025). Update on Surveillance in Von Hippel–Lindau Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-3525
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.